The influence of HIV-1 subtype in the response to therapeutic dendritic cell vaccine

Valéria Ferreira, Patrícia Moura, Sergio Crovella, Ricardo Sobhie Diaz, Adauto Castelo Filho, Ricardo Ximenes, Luiz Cláudio Arraes

Research output: Contribution to journalArticlepeer-review


In the present study, we investigated the influence of HIV-1 subtype in the response to the dendritic cell (DC) therapeutic vaccine for HIV. HIV-1 viral load and TCD8+/TCD4+ cell counts for up to 48 weeks after vaccination. Out of 19 immunized subjects, 13 were infected by subtype B, 5 by subtype F, and 1 by subtype D. Overall, 42.1% (8/19) achieved a viral load decline of 1 log10 sustained up to 48 weeks after immunization. Such magnitude of viral load drop was seen in 80% (4/5) of subtype F infected patients, and in 23.0% (3/13) of the subtype B infected ones (p=0.08). Moreover, mean viral load decline was 1.32 log10, for subtype F infected individuals compared to 0.5 log10 among subtype B infected patients (p=0.01). The variation in TCD4+ cell count was not related to HIV-1 subtype. Larger studies are necessary to confirm the efficacy of this immunotherapy and the differential response according to the background genetic diversity of HIV-1.

Original languageEnglish
Pages (from-to)289-292
Number of pages4
JournalOpen AIDS Journal
Issue number1
Publication statusPublished - 2012


  • Dendritic cells
  • HIV-1 subtype
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'The influence of HIV-1 subtype in the response to therapeutic dendritic cell vaccine'. Together they form a unique fingerprint.

Cite this